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ABSTRACT
Cardiovascular involvement is common in acromegaly and can lead to
development of acromegalic cardiomyopathy, characterized by
concentric biventricular hypertrophy with a progressive impairment of
diastolic and systolic function. The onset of heart failure and
arrhythmias are related to poor prognosis. We report on a case of a 48-
year-old man with acromegalic cardiomyopathy caused by pituitary
adenoma. Despite the successful trans-sphenoidal resection of the
tumour, the patient was rehospitalized for ventricular arrhythmic
storms that led to cardiogenic shock, which required mechanical he-
modynamic support with intra-aortic balloon pump, venoarterial
extracorporeal membrane oxygenation, and urgent heart
transplantation.
RESUME
L’atteinte cardiovasculaire va souvent de pair avec l’acromegalie et
peut se solder par l’apparition d’une cardiopathie acromegalique
caracterisee par une hypertrophie concentrique biventriculaire et une
deterioration progressive des fonctions diastolique et systolique.
L’apparition d’une insufﬁsance cardiaque et d’arythmie est associee à
un pronostic sombre. Nous traitons du cas d’un homme âge de 48 ans
atteint de cardiopathie acromegalique causee par un adenome hypo-
physaire. Malgre la reussite d’une resection trans-sphenoïdale de la
tumeur, le patient a dû être hospitalise de nouveau en raison de
« tempêtes arythmiques ventriculaires » ayant entraîne un choc car-
diogenique, lequel a necessite un soutien hemodynamique mecanique
par pompe à ballonnet intra-aortique, une oxygenation veino-arterielle
par membrane extracorporelle et une transplantation cardiaque
d’urgence.
We report on a 48-year-old man with acromegalic cardio-
myopathy caused by pituitary adenoma.
Case
A 48-year-old man presented in the emergency department
in 2011 for chest pain. Systemic examination revealed coarse
facial features and signs of heart failure. The electrocardiogram
showed sinus rhythm, left bundle branch block, and ectopic
ventricular beats.
Transthoracic echocardiogram revealed a dilated left
ventricular cavity with diffuse hypokinesis, apical throm-
bosis, and ejection fraction of 20%. Coronary angiography
showed normal coronary arteries and cardiac magnetic
resonance imaging conﬁrmed the severe left ventricular
dilatation (indexed telediastolic volume: 195 mL/m2) and
dysfunction (ejection fraction, 22%), eccentric hypertrophy
with apical thrombosis, and transmural ﬁbrosis. At the same
time, the patient was evaluated for acromegaly. Elevated
growth hormone (GH) levels (11.5 ng/mL) and cerebral
magnetic resonance imaging were compatible with pituitary
adenoma. The patient was treated with somatostatin
analogue and the adenoma was successively removed using
trans-sphenoidal resection. After the surgery, the patient
developed secondary adrenal insufﬁciency and cortisone ac-
etate 37.5 mg/d was introduced. With tailored heart failure
therapy, amiodarone and warfarin, the patient remained
asymptomatic. Clinical stability was maintained for 3 years,
until the patient was admitted to our hospital for mono-
morphic sustained ventricular tachycardia (VT) of 170 beats
per minute (Fig. 1), solved with direct current shock. A dual
coil lead implantable cardioverter-deﬁbrillator (ICD) was
placed and amiodarone was interrupted because of iatrogenic
hyperthyroidism.
2After 6 months, the patient was readmitted for repeated
ICD interventions because of VT of 190 beats per minute.
With introduction of procainamide (1.5 g/d orally) no
recurrence of VT was documented and the patient was suc-
cessfully discharged. Unfortunately, 3 months later, the pa-
tient was hospitalized for multiple episodes of VT interrupted
by ICD shock. Electrolytic balance and thyroid hormone
levels were normal. The patient was treated with intravenous
procainamide and amiodarone, both ineffective to prevent
another electrical storm (ES) of sustained VT, then, an intra-
aortic balloon pump (IABP) was placed. Unfortunately,
despite these treatments a new ES with hemodynamic insta-
bility recurred, therefore after 9 days, it was decided to initiate
extracorporeal life support with venoarterial extracorporeal
membrane oxygenation (VA-ECMO) and the patient was
placed on the waiting list for emergent heart transplantation.
However, antiarrhythmic drugs, IABP, and VA-ECMO were
ineffective to prevent the recurrence of VT and a catheter
ablation was scheduled, but the day before the procedure, after
19 days of VA-ECMO, a compatible organ was available and
heart transplantation with bicaval anastomoses was performed.
At macroscopic analysis of the explanted heart, the severe
dilatation and eccentric hypertrophy was conﬁrmed (Fig. 2A).
Histologically, sporadic foci of ﬁbroadipose replacement,
interstitial ﬁbrosis, and ﬁbrous thickening of the endocardium
without inﬂammation (Fig. 2B) was highlighted. There were
not immediate perioperative complications. The pituitary
function was normal. Before transplantation GH and insulin-
like growth factor-1 levels were 1.96 ng/mL and 322 ng/mL,
respectively, whereas after transplantation GH was 1.48 ng/
mL and insulin-like growth factor-1 was 385 ng/mL.
The current immunosuppressive therapy consists of
cyclosporine 50 mg twice daily and everolimus 0.50 mg twice
daily without any rejection episodes. Steroid treatment was
suspended 2 years after the transplantation. The lipid proﬁle
was optimally controlled with atorvastatin 40 mg once daily
and glycemia was normal. Echocardiographic evaluations
during follow-up showed normal biventricular function and
coronary angiography did not reveal allograft vasculopathy.
Discussion
The natural history of acromegalic cardiomyopathy is
characterized by progressive impairment of diastolic and sys-
tolic function and when heart failure appears, the prognosis is
poor with a 25% mortality rate at 1 year and 37.5% at 5
years,1,2 but with arrhythmias is approximately 50% and
increase to 85% and 97% when ESs happen.3 There are not
Figure 1. Twelve-lead electrocardiogram of monomorphic ventricular tachycardia. RS aspect in V1 and QS pattern in V2-V6, frontal axis þ230,
suggesting an apical origin in the left ventricle.
Figure 2. (A) Section of the explanted heart; (B) histological analysis showing the interstitial ﬁbrosis (asterisk) and sporadic foci of ﬁbroadipose
replacement (double asterisks).
3The authors have no conﬂicts of interest to disclose.
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speciﬁc treatments to prevent the onset of VT in acromegalic 
cardiomyopathy. Whereas the role of the ICD in the 
prevention of sudden death has been conﬁrmed, with the 
exception of b-blockers, there are not studies that have shown 
the effectiveness of the currently available antiarrhythmic drugs 
in the primary management of patients with life-threatening 
sustained VT.
Regarding the efﬁcacy of the IABP in the treatment of 
incessant VT, studies are inconclusive concerning the speciﬁc 
characteristics of patients in whom IABP support yields 
beneﬁts and the indications of its use, remain subject to 
physicians’ biases and experience, whereas the scarcity of 
patients in randomized trials might explain why there is still 
uncertainty about the appropriate timing of VA-ECMO 
placement in patients with cardiogenic shock.4
To our knowledge, the literature reports only anecdotal 
cases of heart transplantation in acromegalic patients with 
heart failure,5 and there are not cases with malignant 
arrhythmias, treated with cardiac mechanical support and 
heart transplantation. Nevertheless, the limited follow-up of 
26 months of our patient does not allow conclusions to be 
drawn about the long-term prognosis.
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